Using the Epitranscriptome to Diagnose and Treat Diffuse Gliomas
Official title: Using the Epitranscriptome to Diagnose and Treat Gliomas
Run by Institut du Cancer de Montpellier - Val d'Aurelle · NCT06575452 · Data updated 2026-11-12
This study tests whether analyzing epitranscriptomic marks from tumor tissue and body samples can help diagnose and guide treatment for adults with suspected diffuse gliomas undergoing surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 228 (estimated) |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Montpellier, Hérault and 1 other locations) |
| Status | Recruiting |
| Started | June 1, 2026 |
| Main results expected | May 2028 |
| Study ends | May 2031 |
| Registry record updated | June 11, 2026 |
| Trial ID | NCT06575452 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with suspected diffuse glioma scheduled for tumor resection at Montpellier and confirmed by tissue analysis (IDH-mutated grade 2 or 3 glioma, GBM, or IDH wild-type), with no prior glioma treatment.
✕Probably not a fit
Patients with non-diffuse gliomas, without measurable epitranscriptomic signals, or who do not undergo the planned procedures may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study aims to improve classification of diffuse gliomas by examining epitranscriptomic signatures in tumor tissue and biofluids collected during standard care. It notes that intratumoral heterogeneity and sampling bias challenge accurate diagnosis and personalized therapy. Participants include adults with planned tumor resection at Montpellier who have suspected diffuse glioma confirmed on tissue samples. The approach may involve analyzing blood, urine, and tumor tissue to identify molecular patterns that correlate with tumor type and potential treatment responses. The trial collaborates with French cancer institutes to support tissue-based and liquid biopsy analyses.
Why it matters
Potential benefit: If successful, patients could receive more accurate tumor classification and more tailored treatment options based on epitranscriptomic information.
How similar studies have gone: Other studies are exploring molecular and epigenetic signatures to improve glioma classification, with promising but evolving results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male / female over 18 years of age, * Surgery (tumor resection) scheduled at Montpellier University Hospital for suspected, diffuse glioma, confirmed on tissue sample: IDH mutated grade 2 glioma (excluding tumors with a focus of grade 3 or 4 glioma), IDH mutated grade 3 glioma or GBM, IDH wild-type, * No history of treatment (surgery, radiotherapy or chemotherapy) for glioma, * Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures, * Patient has given express written informed consent prior to any study procedure, * Patient affiliated to a French health insurance. Exclusion Criteria: * Patients whose regular follow-up is impossible for psychological, family, social or geographical reasons, * Patients under guardianship, curatorship or safeguard of justice, * Pregnant and/or breast-feeding patient (information gathered from the medical file, as part of the patient's standard medical care and follow-up), * Histo-molecular diagnosis of grade 4 IDH-mutated astrocytoma, * For grade 2 gliomas, presence within the tumor of one or more higher-grade sites (3 or 4).
Where it's running
-
Insitut Régional du Cancer de Montpellier
Montpellier, Hérault, France Recruiting -
CHU Montpellier - Hôpital St Eloi
Montpellier, France Recruiting
Study contacts
- Study coordinator: Aurore MOUSSION
- Email: aurore.moussion@icm.unicancer.fr
- Phone: 467612446
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.